sildenafil vs Tadalafil

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline

sildenafil · Revatio

Marketed by Viatris and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Partial signal

NCT00644605 · Phase 3 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: April 2028 · NCT07824674 (registry estimate)

Reported efficacy

Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test). (Week 12): The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001). (met)

Result source: NCT00644605

Tadalafil · Adcirca

Marketed by Eli Lilly and partners

Approved in Pulmonary Arterial Hypertensionsmall molecule
Weak signal

NCT00549302 · Phase 3 · completed

This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: May 2028 · NCT06968962 (registry estimate)

Reported efficacy

Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters (Baseline, Week 24): 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) (missed)

Result source: NCT01824290

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. sildenafil: 7 of 7 rows · Tadalafil: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsildenafil
Rows use multiple source trials
Tadalafil
Rows use multiple source trials
6MWD - Change
absolute change · m
No placebo or comparator arm
84.2 m @ 12wka,b,c,d,e
NCT00454207 · Phase 3 · registry result, not featured evidence
show 1 more dose
-23.5 m @ 12wk
NCT00454207 · Phase 3 · registry result, not featured evidence
395 m @ 36wkb,c,d,e
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
Borg Dyspnea
absolute change · score
No placebo or comparator arm
0 score @ 24wkc
NCT00159861 · Phase 3
-1 score @ 24wka,c
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
-0.5 score @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
PVR
absolute change · Wood units
No placebo or comparator arm
-6.145 Wood units @ 16wkc,d,f
NCT01642407 · Phase 4 · registry result, not featured evidence
3.1 Wood units @ 36wkc,d,f
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
Dropout rate
—g
NCT00159861 · Phase 3
show 17 more results
2.6%High Dose
NCT00159913 · Phase 3
4.8%Low Dose
NCT00159913 · Phase 3
0%Medium Dose
NCT00159913 · Phase 3
52.2%high dose
NCT00159874 · Phase 3
46.2%low dose
NCT00159874 · Phase 3
42.1%medium dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
55.8%high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
47.6%low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
54.5%medium dose
NCT00159874 · Phase 3
14%
NCT00323297 · Phase 4
50%
NCT01642407 · Phase 4 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00454207 · Phase 3 · registry result, not featured evidence
18%40 mgg
NCT00549302 · Phase 3
show 7 more results
4%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
20.5%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
30.5%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
0%Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
0%Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
0%Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT00159861 · Phase 3
show 17 more results
1.3%High Dose
NCT00159913 · Phase 3
2.4%Low Dose
NCT00159913 · Phase 3
0%Medium Dose
NCT00159913 · Phase 3
8.7%high dose
NCT00159874 · Phase 3
7.7%low dose
NCT00159874 · Phase 3
5.3%medium dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
6.5%high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
4.8%low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
3.6%medium dose
NCT00159874 · Phase 3
4%
NCT00323297 · Phase 4
—
NCT01642407 · Phase 4 · registry result, not featured evidence
—400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
—
NCT00454207 · Phase 3 · registry result, not featured evidence
5.4%40 mgg
NCT00549302 · Phase 3
show 7 more results
—
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
11.3%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
15.9%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
—Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Serious AEs
77.6%g
NCT00159861 · Phase 3
show 17 more results
—High Dose
NCT00159913 · Phase 3
—Low Dose
NCT00159913 · Phase 3
—Medium Dose
NCT00159913 · Phase 3
—high dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
48%high dose
NCT00159874 · Phase 3
—high dose
NCT00159874 · Phase 3
25.5%low dose
NCT00159874 · Phase 3
—low dose
NCT00159874 · Phase 3
50%medium dose
NCT00159874 · Phase 3
—medium dose
NCT00159874 · Phase 3
44%
NCT00323297 · Phase 4
0%
NCT01642407 · Phase 4 · registry result, not featured evidence
5.6%400 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
10.5%200 mg/Day
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
15.9%
NCT00454207 · Phase 3 · registry result, not featured evidence
—40 mgg
NCT00549302 · Phase 3
show 7 more results
12.5%
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
41.1%Combination Therapy: Ambrisentan +
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
45%Tadalafil Monotherapy
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
50%Heavy Weight: ≥40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
—Light Weight <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
16.7%Light Weight: <25 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
57.1%Middle Weight: 25 kg to <40 kg
NCT01484431 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
g
headache 67.9% (placebo 18.8%)
diarrhoea 47.8% (placebo 31.3%)
nausea 47% (placebo 25%)
NCT00159861 · Phase 3
show 11 more results
High Dose
headache 15.6% (placebo 13.3%)
vomiting 14.3% (placebo 6.7%)
pyrexia 10.4% (placebo 1.7%)
NCT00159913 · Phase 3
Low Dose
headache 11.9% (placebo 13.3%)
upper respiratory tract infection 9.5% (placebo 6.7%)
nasopharyngitis 7.1% (placebo 6.7%)
NCT00159913 · Phase 3
Medium Dose
pyrexia 14.5% (placebo 1.7%)
upper respiratory tract infection 14.5% (placebo 6.7%)
headache 10.9% (placebo 13.3%)
NCT00159913 · Phase 3
high dose
upper respiratory tract infection 37%
headache 26%
vomiting 24%
NCT00159874 · Phase 3
low dose
headache 32.7%
pharyngitis 29.1%
nasopharyngitis 27.3%
NCT00159874 · Phase 3
medium dose
upper respiratory tract infection 29.7%
headache 24.3%
bronchitis 21.6%
NCT00159874 · Phase 3
diarrhoea 14% (placebo 9.4%)
headache 14% (placebo 13.2%)
oedema peripheral 14% (placebo 15.1%)
NCT00323297 · Phase 4
bronchitis 50%
nasopharyngitis 50%
upper respiratory tract infection 50%
NCT01642407 · Phase 4 · registry result, not featured evidence
400 mg/Day
vomiting 22.2%
anaemia 16.7%
blood potassium decreased 16.7%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
200 mg/Day
diarrhoea 26.3%
nausea 21.1%
back pain 10.5%
NCT01392469 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 38.6%
headache 25%
flushing 22.7%
NCT00454207 · Phase 3 · registry result, not featured evidence
g
oedema peripheral 44%
headache 41.1%
diarrhoea 20.9%
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 4 more results
headache 36.4%
oedema peripheral 29.1%
dyspnoea 18.5%
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
angina pectoris 33.3%
ear pain 33.3%
headache 33.3%
NCT01484431 · Phase 1/2 · registry result, not featured evidence
gastroenteritis 50%
bronchitis 33.3%
ecchymosis 33.3%
NCT01484431 · Phase 1/2 · registry result, not featured evidence
oropharyngeal pain 42.9%
headache 28.6%
pain in extremity 28.6%
NCT01484431 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 4.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 12 weeks versus 36 weeks.
  6. fAssessment timepoints differ: 16 weeks versus 36 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

sildenafil

EQ-5D Utility 0.0473 score @ 65wk
absolute change · score
No placebo or comparator arm
NCT00159861 · Phase 3
show 2 more results
0.0483 score @ 117wk
NCT00159861 · Phase 3
0.077 score @ 169wk
NCT00159861 · Phase 3
EQ-5D VAS 12.8 score @ 65wk
absolute change · score
No placebo or comparator arm
NCT00159861 · Phase 3
show 2 more results
11.2 score @ 117wk
NCT00159861 · Phase 3
11.5 score @ 169wk
NCT00159861 · Phase 3
Peak VO2 6.44% (n=24) vs 0.53% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 5 more results
13.4% (n=26) vs 0.53% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
10.58% (n=27) vs 0.53% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
5.43% (n=23) vs 2.81% (n=24) placebo @ 16wkLow Dose
NCT00159913 · Phase 3
15.66% (n=23) vs 2.81% (n=24) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
9.34% (n=27) vs 2.81% (n=24) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
mPAP 0.9 vs -0.4 placebo mmHg @ 16wkLow Dose
absolute change · mmHg
NCT00159913 · Phase 3
show 2 more results
-3.9 vs -0.4 placebo mmHg @ 16wkMedium Dose
NCT00159913 · Phase 3
-7.4 vs -0.4 placebo mmHg @ 16wkHigh Dose
NCT00159913 · Phase 3
PVRI 0.1 vs 1.6 placebo wood units. m2 @ 16wkLow Dose
absolute change · wood units. m2
NCT00159913 · Phase 3
show 2 more results
-2.9 vs 1.6 placebo wood units. m2 @ 16wkMedium Dose
NCT00159913 · Phase 3
-5.1 vs 1.6 placebo wood units. m2 @ 16wkHigh Dose
NCT00159913 · Phase 3
RER 0% (n=24) vs -0.03% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 2 more results
-0.05% (n=26) vs -0.03% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
-0.02% (n=27) vs -0.03% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
Time to Max VO2 64.83% (n=24) vs 8.84% (n=29) placebo @ 16wkLow Dose
percent change · % of baseline
NCT00159913 · Phase 3
show 2 more results
64.42% (n=26) vs 8.84% (n=29) placebo @ 16wkMedium Dose
NCT00159913 · Phase 3
31.33% (n=27) vs 8.84% (n=29) placebo @ 16wkHigh Dose
NCT00159913 · Phase 3
Pulmonary Vascular Resistance -0.1 vs 0.1 placebo wood units @ 16wkLow Dose
absolute change · wood units
NCT00159913 · Phase 3
show 2 more results
-3.3 vs 0.1 placebo wood units @ 16wkMedium Dose
NCT00159913 · Phase 3
-5.2 vs 0.1 placebo wood units @ 16wkHigh Dose
NCT00159913 · Phase 3
Cardiac Index Change L/Min M2 0.2 vs -0.6 placebo m @ 16wkLow Dose
absolute change · m
NCT00159913 · Phase 3
show 2 more results
0.02 vs -0.6 placebo m @ 16wkMedium Dose
NCT00159913 · Phase 3
0.24 vs -0.6 placebo m @ 16wkHigh Dose
NCT00159913 · Phase 3
Right Atrial Pressure 7.92 vs 8.11 placebo mmHg @ 16wkLow Dose
absolute change · mmHg
NCT00159913 · Phase 3
show 2 more results
8.05 vs 8.11 placebo mmHg @ 16wkMedium Dose
NCT00159913 · Phase 3
7.75 vs 8.11 placebo mmHg @ 16wkHigh Dose
NCT00159913 · Phase 3
CHQ-PF28, Physical 14 vs 8.3 placebo score @ 16wkLow Dose
absolute change · score
NCT00159913 · Phase 3
show 2 more results
9.8 vs 8.3 placebo score @ 16wkMedium Dose
NCT00159913 · Phase 3
5.9 vs 8.3 placebo score @ 16wkHigh Dose
NCT00159913 · Phase 3
CHQ-PF28, Psychosocial 5.1 vs 5.6 placebo score @ 16wkLow Dose
absolute change · score
NCT00159913 · Phase 3
show 2 more results
4.1 vs 5.6 placebo score @ 16wkMedium Dose
NCT00159913 · Phase 3
4.3 vs 5.6 placebo score @ 16wkHigh Dose
NCT00159913 · Phase 3

+ 48 further endpoints in the CSV export.

Tadalafil

PAH Deterioration Free 96% (n=294) @ 16wk40 mg
absolute value · percentage points
No placebo or comparator arm
NCT00549302 · Phase 3
show 7 more results
90% (n=294) @ 28wk40 mg
NCT00549302 · Phase 3
88% (n=294) @ 40wk40 mg
NCT00549302 · Phase 3
85% (n=294) @ 52wk40 mg
NCT00549302 · Phase 3
95% (n=63) @ 16wk20 mg
NCT00549302 · Phase 3
88% (n=63) @ 28wk20 mg
NCT00549302 · Phase 3
81% (n=63) @ 40wk20 mg
NCT00549302 · Phase 3
81% (n=63) @ 52wk20 mg
NCT00549302 · Phase 3
RV Mass Change 28 g @ 36wk
absolute change · g
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
TAPSE Change 1.65 cm @ 36wk
absolute change · cm
No placebo or comparator arm
NCT01042158 · Phase 4 · registry result, not featured evidence · combination
Clinical Failure 18.2% (n=253) @ 87wk
event rate · % of participants
No placebo or comparator arm
First adjudicated clinical failure event
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 46 Participants as posted
show 1 more result
28.1% (n=121) @ 87wk*
First adjudicated clinical failure event
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 34 Participants as posted
All-cause Mortality 3.6% (n=253) @ 87wk
absolute value · percentage points
No placebo or comparator arm
Death (all-cause)
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted
show 1 more result
5% (n=121) @ 87wk*
Death (all-cause)
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 Participants as posted
Disease Progression Event 4% (n=253) @ 87wk
event count · % of participants
No placebo or comparator arm
Disease progression
NCT01178073 · Phase 3 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted
show 1 more result
3.3% (n=121) @ 87wk*
Disease progression
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 4 Participants as posted
NT-Pro BNP -67.15% (n=204) @ 24wk
percent change · % of baseline
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-43.83% (n=100) @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
Satisfactory Clinical 39% (n=234) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
27% (n=113) @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
WHO Functional Class 0 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT01178073 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0 score @ 24wk
NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy
Clinical Worsening 50% (n=6)
responder rate · % of participants
No placebo or comparator arm
NCT01484431 · Phase 1/2 · registry result, not featured evidence
show 2 more results
28.57% (n=7)
NCT01484431 · Phase 1/2 · registry result, not featured evidence
33.33% (n=6)
NCT01484431 · Phase 1/2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: sildenafil's landscape · Tadalafil's landscape